Clinical trial
Pharmacokinetic Study of Palifermin in Subjects Receiving Radiation Therapy and…
NCT00070616 · Swedish Orphan Biovitrum, Industry · Completed
Key facts
| NCT number | NCT00070616 |
|---|---|
| Title | Pharmacokinetic Study of Palifermin in Subjects Receiving Radiation Therapy and Chemotherapy Followed by Blood Stem Cell Support |
| Official title | An Open-label Study of the Pharmacokinetics (PK) of Recombinant Human Keratinocyte Growth Factor (Palifermin; rHuKGF) in Subjects With Hematologic Malignancies Undergoing Total Body Irradiation and High-dose Chemotherapy Followed by Peripheral Blood Progenitor Cell (PBPC) Transplantation |
| Lead sponsor | Swedish Orphan Biovitrum, Industry |
| Collaborators | Amgen Industry |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Leukemia, Lymphoma, Myeloma |
| Intervention type | Drug, Radiation |
| Interventions | Palifermin 6 x 60 μg/kg/day, Palifermin 2 x 180 μg/kg/day, radiotherapy, Chemotherapy |
| Enrollment | 25 |
| Start date | Dec 1, 2001 |
| Primary completion | Mar 1, 2005 |
| Completion | Mar 1, 2005 |
| First posted | Oct 8, 2003 |
| Last update posted | Oct 24, 2014 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: